This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin
catalog :
TN8-H5250
quantity :
1 mg, 100 ug
price :
2100 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
TN8-H5250
product name :
Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin
quantity :
1 mg, 100 ug
price :
2100 USD, 350 USD
quantity & price :
$350/100ug,$2100/1mg (500ug × 2)
target :
CD30
host species :
Human
By Tag :
Llama IgG Fc Tag
Research :
For Research Use Only
Source :
Human CD30, Llama IgG2b Fc Tag, low endotoxin (TN8-H5250) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2).
Endotoxin :
Less than 0.01 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CD30, Llama IgG2b Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
References :
(1) Gorczyca W., et al., 2003, Int. J. Oncol. 22 (2): 319-324.
(2) Aizawa S., et al., 1997, J. Biol. Chem. 272 (4): 2042-2045.
(3) Ansieau S., 1996, Proc. Natl. Acad. Sci. U.S.A. 93 (24): 14053-14058.
(4) Lee S.Y., et al., 1996, J. Exp. Med. 183:669-674.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments